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Infective endocarditis due to vancomycin-resistant (VR) Enterococcus faecalis has only rarely been reported.
We report a case of VR E. faecalis endocarditis that failed to respond to linezolid therapy, outline the virulence
traits of the isolate, and review previously published cases of VR E. faecalis endocarditis.
CASE REPORT
A 37-year-old female was transferred to our institution for
hemodialysis access and sustained vancomycin-resistant (VR)
Enterococcus faecalis bacteremia. Her medical history was sig-
nificant for medullary cystic kidney disease diagnosed at age 7,
and she had required hemodialysis since age 10. She had four
failed renal allografts, the first transplant having been per-
formed at age 11. In addition, she had multiple failed arterio-
venous grafts and fistulas, requiring placement of bilateral
subclavian subcutaneous hemodialysis ports (LifeSite Hemo-
dialysis Access System) 3 years prior to admission.
Seven months prior to admission, she developed methicillin-
resistant Staphylococcus aureus bacteremia secondary to infec-
tion of her hemodialysis ports and was treated with 4 weeks of
intravenous vancomycin. Two months prior to admission, she
developed VR E. faecalis bacteremia secondary to hemodial-
ysis port infection. The VR E. faecalis blood isolate was sen-
sitive to penicillin, ampicillin, linezolid, high-level streptomycin
(MIC, 1,000 g/ml), and rifampin and resistant to high-level
gentamicin (MIC, 500 g/ml), erythromycin, and tetracy-
cline. Due to a history of penicillin allergy, oral linezolid was
given for 4 weeks. The hemodialysis ports were not removed at
that time due to difficulty with obtaining additional vascular
access. No valvular or catheter-associated vegetations were
demonstrated on transesophageal echocardiography.
She was subsequently admitted to another institution for
evaluation of fever and chills. Two sets of blood cultures grew
VR E. faecalis with a susceptibility pattern similar to that of the
previous VR E. faecalis blood isolate obtained 2 months prior.
Linezolid, given 600 mg intravenously every 12 h, was initiated.
Blood cultures remained positive for VR E. faecalis on hospi-
talization day 2. Both subclavian subcutaneous hemodialysis
ports were removed on hospitalization day 3, and bacterial
culture of the catheter tips grew VR E. faecalis.
The patient was transferred to our institution on hospital-
ization day 5. At hospital admission, her body temperature was
35.7°C, her blood pressure was 80/48 mmHg, and her heart
rate was 101 beats/min. Physical examination did not reveal a
cardiac murmur or peripheral stigmata of endocarditis. Labo-
ratory testing showed a peripheral leukocyte count of 12,300/
mm3. Two sets of blood cultures grew VR E. faecalis within
24 h; the blood isolate was sensitive to penicillin, ampicillin,
linezolid, and daptomycin and resistant to quinupristin-dalfo-
pristin and erythromycin. The isolate was resistant to high-level
gentamicin (MIC, 500 g/ml), although it lacked high-level
resistance to streptomycin (MIC, 2,000 g/ml). In addition,
the isolate contained the vanA gene by PCR analysis.
Additional blood cultures taken on hospitalization days 7
and 9 were positive for VR E. faecalis, despite continued ther-
apy with linezolid. A transesophageal echocardiogram on hos-
pitalization day 7 showed mobile aortic valve vegetations
(8-mm and 4-mm vegetations), a mobile mitral valve vegeta-
tion (10 by 8 mm), new mitral valve regurgitation, and new
moderate-to-severe aortic valve regurgitation. She had more
than 10 reported allergies, including penicillin, amoxicillin, ce-
fazolin, tetracycline, and ciprofloxacin. Skin testing for penicil-
lins and cephalosporins was performed and was negative. An-
tibiotic therapy was changed from intravenous linezolid to
aqueous crystalline penicillin G sodium, 3  106 U given in-
travenously every 6 h, plus streptomycin, 300 mg given intra-
venously three times weekly, after each hemodialysis. Strepto-
mycin levels were monitored. She improved clinically, and
follow-up blood cultures performed on hospitalization day 15
were negative. She received 6 weeks of combined treatment
with intravenous penicillin G and streptomycin. Relapsing VR
E. faecalis bacteremia did not occur over the 9 months follow-
ing the completion of antibiotic therapy.
Colony lysates of the VR E. faecalis blood isolate from
hospitalization day 5 (TX2853) were prepared by previously
described methods (29) and hybridized with probes represent-
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ing 17 genes that encode proven or suspect virulence determi-
nants. These included the gelatinase gene (22, 26, 28, 30);
recently described pilus-encoding genes (16); genes encoding
putative MSCRAMMs (microbial surface components recog-
nizing adhesive matrix molecules) with predicted immunoglob-
ulin (Ig)-like folds (17, 18, 27; J. Sillanpa¨a¨, S. R. Nallapareddy,
and B. E. Murray, unpublished data); genes, including esp (33),
in a predicted pathogenicity island (PAI) (15); and an acquired
gene that contributes to biofilm formation (32) (Table 1). The
strain was examined for phenotypic production of gelatinase
(22), hemolytic activity on Bacto Tryptic Soy Agar (Becton
Dickinson and Company, Sparks, MD) plus 5% human blood
agar plates, and biofilm formation (14). DNA was extracted
with a DNeasy tissue kit (QIAGEN Sciences, Maryland) by
following the manufacturer’s instructions and tested by PCR as
previously described to determine if the conserved junction of
the PAI with chromosomal DNA was present (15). Pulsed-field
gel electrophoresis and multilocus sequence typing of internal
regions of five housekeeping genes were performed to deter-
mine if TX2853 belonged to the previously described beta-
lactamase, vancomycin-resistant, endocarditis clone (15).
TX2853 produced gelatinase; it also contained five of seven
putative adhesin genes (including the ebpA and ebpB genes,
which are related to pilus formation), one of two predicted
hyaluronidase genes, esp, and two of six other PAI genes. The
common PAI-chromosome junction point previously described
(15) was also present. TX2853 tested negative by PCR for the
bee (biofilm enhancer in enterococcus) locus (32). By pulsed-
field gel electrophoresis and multilocus sequence typing, this
strain did not belong to the beta-lactamase, vancomycin-resis-
tant, endocarditis clone (or to one of the sequence types we
have previously classified by this system). Biofilm assay showed
that the strain was a medium biofilm producer (33). TX2853
tested negative for hemolytic activity on blood agar plates,
which is consistent with cylM probe negative results.
Vancomycin-resistant enterococci have emerged as a well-
defined cause of health care-associated and nosocomial infec-
tions (5, 8). Despite the increasing prevalence of vancomycin-
resistant enterococci in most tertiary-care and other health
care settings, infective endocarditis due to these organisms has
been reported in only a limited number of cases (31). More-
over, endocarditis due to VR E. faecalis isolates is extremely
rare. We performed a review of the PubMed database (English
language) through the end of September 2006 with the search
terms “vancomycin resistant enterococcus endocarditis” and
“glycopeptide resistant enterococcus endocarditis.” An article
was included in our review if it described a case of VR E.
faecalis infective endocarditis that fulfilled the modified Duke
criteria for definite or possible infective endocarditis (13).
There were only six previously reported cases of infective en-
docarditis caused by VR E. faecalis that met our criteria (Table
2). Two cases met criteria for definite infective endocarditis
(patients 1 and 3), and four cases met criteria for possible
infective endocarditis (patients 2, 4, 5, and 6). In the majority
of previously reported cases of VR E. faecalis infective endo-
carditis in our review, the mitral or aortic valve was affected;
our case report represents the first description of bivalvular
endocarditis due to VR E. faecalis. Only one of seven isolates
was resistant to ampicillin, which is consistent with the rates of
ampicillin resistance (between 0.9 and 2.7%) observed in E.
faecalis isolates in the United States (5, 8). The mechanism of
resistance to ampicillin in the isolate from patient 5 (Table 2)
was not mentioned in the case report (7). Most patients were
TABLE 1. Potential virulence- and PAI-associated genes
Locus Gene name/function TX2853 HShybridization Reference(s)
Virulence associated
ef1091 ebpA/endocarditis- and biofilm-associated pili  16
ef1092 ebpB/endocarditis- and biofilm-associated pili  16
ef1818 gelE/protease  22
ef1824 Glycosyl hydrolase, family 31/fibronectin type III domain protein with
Ig-like fold-containing putative surface adhesin
 15, 27
ef3023 hylA/putative hyaluronidase  15, 27
ef1896 Cell wall surface anchor family protein with Ig-like fold-containing
putative surface adhesin
 Sillanpa¨a¨ et al.,
unpublished
ef2347 Cell wall surface anchor family protein with Ig-like fold-containing
putative surface adhesin
 Sillanpa¨a¨ et al.,
unpublished
ef2505 Cell wall surface anchor family protein with Ig-like fold-containing
putative surface adhesin
 Sillanpa¨a¨ et al.,
unpublished
ef0818 hylB/putative hyaluronidase  15
ef1099 ace/collagen adhesin protein  17, 18
PAI associated
ef0482 Hypothetical protein  15
ef0521 cbh/putative choloylglycine hydrolase family protein  15, 24
ef0527 cylM/cytolysin  15, 24
espa esp/enterococcal surface protein  15, 24, 25
ef0556 xylA/putative xylose isomerase  15, 24
ef0571 Putative DNA-binding response regulator  15, 24
ef0604 gls24-like gene  15, 24
a The DNA probe for the esp gene was amplified from strain MMH594, and those for all other genes were amplified from V583 (19).
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treated with either ampicillin or penicillin, and synergistic bac-
tericidal combination therapy with an aminoglycoside was
given to four patients. There were two deaths, and two patients
required valve replacement.
Although there are some case reports of linezolid efficacy for
infective endocarditis due to vancomycin-resistant Enterococ-
cus faecium (31), there has been very limited experience with
the use of linezolid to treat infective endocarditis due to VR E.
faecalis. In the six previously reported cases of VR E. faecalis
in our review, only two of the patients were treated with lin-
ezolid (Table 2, patients 5 and 6). Patient 5 was treated with
linezolid for 6 weeks because he had an ampicillin-resistant
strain of VR E. faecalis (7). He had multiple negative surveil-
lance blood cultures during antibiotic therapy, although he
died from an unknown cause 1 week after completion of lin-
ezolid therapy. Patient 6 was treated with linezolid for 12
weeks plus gentamicin for 6 weeks because of a previous ana-
phylactic reaction to penicillin (35). Six weeks after discontin-
uation of linezolid, blood cultures were positive for VR E.
faecalis although subsequent blood cultures remained negative
for 52 months of follow-up time. Our patient had persistent
VR E. faecalis bacteremia for 9 days while on linezolid therapy
but was subsequently cured after starting therapy with aqueous
crystalline penicillin G sodium plus streptomycin. Based on the
limited and conflicting data in these case reports, further studies
are needed to elucidate the role of linezolid in the treatment of
infective endocarditis due to VR E. faecalis.
Although there are multiple virulence factors that may con-
tribute to the ability of enterococci to cause infective endocar-
ditis, there have been limited studies of virulence traits in VR
E. faecalis infective endocarditis isolates due to its rarity (Table
2). Our patient’s VR E. faecalis infective endocarditis strain
(TX2853) tested positive for five of seven genes thought to be
involved in adhesion (ebpA, ebpB, ace, and two cell surface
anchor family proteins with Ig-like fold-containing putative
surface adhesin), enterococcal surface protein gene esp, gela-
tinase gene gelE, one of two putative hyaluronidase genes
(hylA), and two of six PAI genes (xylA, which encodes a hypo-
thetical protein) (Table 1). In addition, the strain was a me-
dium biofilm producer by biofilm assay and tested negative for
hemolytic activity on blood agar plates.
Microbial adherence to host cells is a pivotal stage in infec-
tion pathogenesis, regardless of the organism or infection syn-
drome. E. faecalis strains recovered from patients with endo-
carditis have a greater capacity to adhere to Girardi heart cells
than to urinary tract epithelial cells in vitro (6), which suggests
that adherence to vascular endothelium may be important.
MSCRAMMs mediate binding of bacteria to extracellular ma-
trix proteins and function as adhesins to damaged heart tissue
(17, 18, 27). Ace is a specific collagen-binding adhesin of the
MSCRAMM family, has been identified in E. faecalis endo-
carditis isolates (17), and mediates attachment of E. faecalis to
collagen types I and IV and laminin (18). Subsequently, a
family of seven genes encoding MSCRAMM-like proteins was
found in 100% (nine out of nine) of the E. faecalis endocarditis
strains tested, and elevated titers of IgG to these MSCRAMM-
like proteins were found in the sera of nine patients with E.
faecalis infections (27). Three of these genes, ebpA, ebpB, and
ebpC (endocarditis- and biofilm-associated pili), control sur-
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face pilus formation and may be important in endocarditis
pathogenesis (16).
Biofilm formation, which is modulated by many genes, in-
cluding esp and the fsr locus, likely serves as an important
factor in E. faecalis infections (16, 32). In one study, E. faecalis
endocarditis isolates produced biofilm more often than did E.
faecalis isolates from nonendocarditis sources and from hospi-
tal fecal specimens (14). The esp gene, which encodes an en-
terococcal surface protein (Esp), plays an important role in
biofilm formation (33) and has been identified more often
among E. faecalis isolates that cause endocarditis and other
bloodstream infections than in E. faecalis fecal isolates (14).
A quorum-sensing fsr locus has recently been described that
regulates the transcription of a gelatinase gene (gelE) and a
serine protease gene (sprE) and could contribute to E. faecalis
virulence (22, 26, 28). The fsr locus regulates biofilm formation
(14, 20). One study showed that 100% (12 out of 12) of the E.
faecalis endocarditis isolates tested had fsr compared to only
53% (10 out of 19) of the fecal isolates tested (21). In contrast,
two subsequent studies did not show an increased prevalence
of fsr in E. faecalis endocarditis and bloodstream isolates (11,
23). In a rat endocarditis model, an E. faecalis mutant that did
not produce gelatinase or serine protease had an endocarditis
induction rate that was significantly reduced compared to that
of wild-type E. faecalis (28). Further investigation is needed to
elucidate the role of the fsr locus in the pathogenesis of E.
faecalis infective endocarditis.
There are several other potential virulence traits of entero-
cocci that could be operative in endocarditis pathogenesis.
These include aggregation substance (1, 12); multiple genes
located in a PAI, including xylA, cbh, one that encodes a hy-
pothetical protein, and others (15, 24); hyaluronidases (15);
extracellular superoxide production (9); and cytolysins-hemo-
lysins (1, 8, 10, 30).
There is only one previous description of pathogen virulence
factors in a patient with VR E. faecalis infective endocarditis
(2, 4) (Table 2, patient 3). That patient’s isolate was similar to
our strain (TX2853) in that it was positive for ace, was a biofilm
producer, and did not display hemolytic activity. In contrast to
our patient’s isolate, that strain was esp negative. Although a
molecular examination for the gelatinase gene (gelE) was not
performed, phenotypically, the strain did not produce gela-
tinase. The strain was positive for the asa1 (aggregation sub-
stance) gene.
In conclusion, we report a case of VR E. faecalis endocar-
ditis that failed to respond to linezolid therapy and review
previously published cases of VR E. faecalis infective endocar-
ditis. More information is needed in order to establish the role
of linezolid in the treatment of VR E. faecalis endocarditis. In
addition, we have also outlined the virulence traits of our
patient’s isolate. Further studies are needed to identify which
virulence factors are operative in the pathogenesis of VR E.
faecalis infective endocarditis and may lead to potential targets
for novel therapeutic agents. Subsequent investigations should
also include etiologic and prognostic cohort studies of patients
with enterococcal bacteremia and infective endocarditis to
identify which virulence traits play a role in the development of
endocarditis and which affect outcome.
This work was supported in part by NIH grant R37 AI47923 from
the Division of Microbiology and Infectious Diseases to B. E. Murray.
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